Eversept Partners’s Maravai LifeSciences MRVI Stock Holding History

Eversept Partners’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-24,000	Closed	-$613K	–	77
2022 Q3	$613K	Buy	+24,000	New	+$602K	0.05%	62

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Eversept Partners's MRVI Position: Q1 2026 in Review

Eversept Partners sold out of Maravai LifeSciences (MRVI) in Q1 2026, closing a stake of 718,582 shares — an estimated $2.34M sold.

Eversept Partners first reported a position in MRVI in Q2 2021 and held it in 11 quarters. The position peaked at $16.1M in Q3 2021. 158 funds tracked by Wall St. Rank hold MRVI as of Q1 2026.

Eversept Partners reported no remaining Maravai LifeSciences position as of Q1 2026 after selling out during the quarter.
Eversept Partners sold 718,582 Maravai LifeSciences shares in Q1 2026, an estimated $2.34M.
Eversept Partners first reported a position in Maravai LifeSciences in Q2 2021 and held it in 11 quarters.
Eversept Partners's Maravai LifeSciences position peaked at $16.1M in Q3 2021.
158 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2026.

Based on Eversept Partners's 13F filing for Q1 2026, filed 15 May 2026.